McKesson Impairment Charges decreased by 97.7% to $2.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 33.3%, from $3.00M to $2.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase signals potential operational issues, poor past investment decisions, or adverse market conditions for specific business units.
These are non-cash charges recorded when the carrying value of an asset exceeds its fair market value. They indicate tha...
Often seen during restructuring or economic downturns across industrial sectors.
impairment_charges_cf| Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.00M | $2.00M | $162.00M | $0.00 | $28.00M | $0.00 | $44.00M | $28.00M | $48.00M | $7.00M | $3.00M | $1.00M | $6.00M | $88.00M | $2.00M |
| QoQ Change | — | -98.1% | >999% | -100.0% | — | -100.0% | — | -36.4% | +71.4% | -85.4% | -57.1% | -66.7% | +500.0% | >999% | -97.7% |
| YoY Change | — | — | — | -100.0% | — | -100.0% | -72.8% | — | +71.4% | — | -89.3% | -97.9% | -14.3% | — | -33.3% |
| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|
| International | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M |
| Total | $0.00 | $28.00M | $0.00 | $44.00M | $28.00M | $48.00M | $7.00M | — |
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.